Insilico Medicine develops new deep-learning based hematological human aging clock

Today, Insilico Medicine, Inc., a Baltimore-based company specializing in the application of artificial intelligence for drug discovery, biomarker development and aging research, announced a publication of a research paper titled “Population-specific biomarkers of human aging: a big data study using South Korean, Canadian and Eastern-European patient populations” in The Journal of Gerontology.